IRAK1 and neoplasm: Using in vitro and in vivo studies, they demonstrated that high levels of IRAK1 in HCC enhance the expression of AKR1B10, a downstream effector of AP-1 and a main regulator of tumor-initiating cells (TICs), thereby promoting doxorubicin or sorafenib resistance.